Sunitinib re-challenge in metastatic renal cell carcinoma treated sequentially with tyrosine kinase inhibitors and everolimus

Anticancer Research

Volumn 31, Issue 10, 2011, Pages 3507-3510

  Paule, Bernard ^a   Brion, Nathalie ^b,c  

^a HENRI MONDOR HOSPITAL   (France)

^b CENTRE HOSPITALIER DE VERSAILLES   (France)

^c LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

Metastatic renal cell carcinoma; mTOR inhibitor; Sequential treatment regimen; Sunitinib; Tyrosine kinase inhibitor

Indexed keywords

CYTOKERATIN 7; EVEROLIMUS; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MORPHINE; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR; PREDNISONE; SORAFENIB; SUNITINIB; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; ZOLEDRONIC ACID;

ADULT; ARTICLE; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SIZE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REDUCTION; DRUG RECHALLENGE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LAPAROSCOPIC SURGERY; LUNG METASTASIS; METASTATIC RENAL CELL CARCINOMA; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE DRUG DOSE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MIDDLE AGED; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS; PYRROLES; SIROLIMUS;

EID: 80054725716     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS, Patard JJ, Mulders PF and Sinescu IC: EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 58: 398-406, 2010.
2. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebeis M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R and Bukowski RM: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125-134, 2007. (Pubitemid 46089673)
3. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Granwald V, Thompson JA, Figlin RA, Hollaender N, Kay A and Ravaud A: Phase 3 trial of everolimus for metastatic renal cell Carcinoma: final results and analysis of prognostic factors. Cancer 116: 4256-4265, 2010.
4. Blesius A, Beuzelink B, Chevreau C, Ravaud A, Rolland F, Oudard S and Escudier B: Are TKIs still active in patients treated with TKI and everolimus? Experience from 36 patients treated in France in the RECORD 1 trial [abstract: 908P]. Paper presented at: 35th ESMO Congress, 8-12 October, 2010, Milan, Italy.
5. Paule B, Deslandes E, Le Mouel SP, Bastien L, Podgorniak MP, Allory Y, de la Taille A, Menashi S, Calvo F and Mourah S: Identification of a novel biomarker signature associated with risk for bone metastasis in patients with renal cell carcinoma. Int J Biol Markers 25: 112-115, 2010.
6. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET and Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655, 1982. (Pubitemid 13149996)
7. Motzer RJ, Bukowski RM, Figlin RA, Hutson TE, Michaelson MD, Kim ST, Baum CM and Kattan MW: Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer 113: 1552-1558, 2008.
8. Calvo E, Motzer RJ, Hutson TE, Oudard S, Porta C, Grunwald V, Figlin RA, Ravaud A, Kpamegan E and Berg W. Phase 3 RECORD-1 study of everolimus in metastatic renal cell carcinoma (MRCC): subgroup analysis of patients with 1 versus 2 prior vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies [abstract: 911P]. Paper presented at: 35th ESMO Congress, 8-12 October, 2010, Milan, Italy.
9. Tamaskar I, Shaheen P, Wood L, Hodnick S, Nemec C, Garcia J, Dreicer R, Rini B and Bukowski R: Antitumor effects of sorafenib and sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC) who had prior therapy with anti-angiogenic agents [abstract]. J Clin Oncol 24: 4597, 2006.
10. Oudard S: More than 4 years of progression-free survival in a patient with metastatic renal cell carcinoma treated sequentially with sunitinib, everolimus, sorafenib, and temsirolimus. Anticancer Res 30: 5223-5225, 2010.
11. Sablin MP, Negrier S, Ravaud A, Oudard S, Balleyguier C, Gautier J, Celier C, Medioni J and Escudier B: Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol 182: 29-34; discussion 34, 2009.
12. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG and Kerbel RS: Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15: 232-239, 2009.
13. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D and Casanovas O: Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15: 220-231, 2009.
14. Loges S, Mazzone M, Hohensinner P and Carmeliet P: Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 15: 167-170, 2009.
15. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, Reichling LJ, Sim T, Sabatini DM and Gray NS: An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 284: 8023-8032, 2009.
16. Roccaro AM, Sacco A, Husu EN, Pitsillides C, Vesole S, Azab AK, Azab F, Melhem M, Ngo HT, Quang P, Maiso P, Runnels J, Liang MC, Wong KK, Lin C and Ghobrial IM: Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia. Blood 115: 559-569, 2010.
17. Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D and Shokat KM: Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 7: e38, 2009.
18. Sarbassov DD, Guertin DA, Ali SM and Sabatini DM: Phosphorylation and regulation of AKT/PKB by the rictor mTOR complex. Science 307: 1098-1101, 2005. (Pubitemid 40262113)
19. Rini BI, Hutson TE, Elson P, Heng DY, Knox JJ, D. M, Choueiri TK and Escudier BJ: Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma [abstract 319]. Paper presented at: American Society for Clinical Oncology - Genitourinary Cancers Symposium 2010, San Francisco, CA.
20. Palmieri D, Lockman PR, Thomas FC, Hua E, Herring J, Hargrave E, Johnson M, Flores N, Qian Y, Vega-Valle E, Taskar KS, Rudraraju V, Mittapalli RK, Gaasch JA, Bohn KA, Thorsheim HR, Liewehr DJ, Davis S, Reilly JF, Walker R, Bronder JL, Feigenbaum L, Steinberg SM, Camphausen K, Meltzer PS, Richon VM, Smith QR and Steeg PS: Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks. Clin Cancer Res 15: 6148-6157, 2009.
21. Paule B and Brion N: Efficacy of sunitinib in patients with renal cell carcinoma with bone metastases. Anticancer Res 30: 5165-5168, 2010.
22. Zolnierek J, Nurzynski P, Langiewicz P, Oborska S, Wasko-Grabowska A, Kuszatal E, Obrocka B and Szczylik C: Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases. J Cancer Res Clin Oncol 136: 371-378, 2010.